Innospec stock
IOSPNASDAQInnospec Inc., Basic MaterialsISIN US45768S1050
64Score 64 out of 100, Neutral
Price and trend
43 / 100
Price history
+5.7% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.4% below it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 19).
The price is 22% below its 52-week high. Largest decline in 20 years: 91% (July 2007 to March 2009).
Chart figures for advanced users
- SMA 50$94.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$84.52
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)19
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$65.89
- The lowest closing price of the last twelve months.
- Resistance$101.41
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Innospec Inc. belongs to the Chemicals (Specialty) industry (United States) and, with a market value of $1.95B, is number 84 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.78B (down 3.7% year on year) and earnings of $116.6M (up 227.5%).
- MEQIRI Score 64 out of 100 (Neutral): rank 148 of 467 in Basic Materials, median 58.
Show more
- The P/E is 13.9 (Chemicals (Specialty) median 24.4, own median of recent years 22.3).
- Our model puts fair value at $123.11, with the price 36% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 32% a year since 2020.Growth 62
- More cash than debtCash $251.9M, financial debt $47.3M.Stability 93
- Modestly valuedP/E 13.9, Chemicals (Specialty) median 24.4, own median 22.3.Valuation 87
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and valuation, while momentum and technical analysis hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 63 to 64.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $94.70 and expensive above $175.87 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $108.04 (cash-flow model) and $138.17 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $113.73, at 7.8% it would be $137.20.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (24.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.7% on the twelve months before. Revenue has grown solidly since 2006, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 28%, operating 9%, net 7%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 16 Feb 2027in 96 days
- Last reported
- 3 Nov 2026EPS reported $1.29 (expected $1.26)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.93−0.1%
- Revenue
- $1.9B−0.1%
- Earnings per share
- $6.00−2.4%
- Revenue
- $2.01B−0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +5.6%Further operating income growth expected in the second half, but some gross margin pressure in the third quarter, which should look much like the second.
“Fuel specialties had another strong quarter, delivering revenue and operating income growth with margins in our target range. While there may be some margin headwind in the sequential quarter, because of the lag between pricing and cost inflation, we expect a continued strong performance.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Jones David B.Sale
3 Mar 2026, SVP, GC & CCO
- Shares
- 1,028
- Price
- $75.64
- Value
- $77,758
- Blackmore Milton CSale
27 Feb 2026, Board
- Shares
- 594
- Price
- $76.55
- Value
- $45,473
- PADFIELD LarrySale
27 Feb 2026, Board
- Shares
- 594
- Price
- $76.55
- Value
- $45,473
Show 5 more
- Poccia ClaudiaSale
27 Feb 2026, Board
- Shares
- 119
- Price
- $76.56
- Value
- $9,110
- Landless DavidSale
27 Feb 2026, Board
- Shares
- 594
- Price
- $76.55
- Value
- $45,473
- Cleminson IanSale
27 Feb 2026, EVP & CFO
- Shares
- 2,380
- Price
- $76.55
- Value
- $182,197
- Blackmore Milton CSale
27 Feb 2026, Board
- Shares
- 594
- Price
- $76.56
- Value
- $45,474
- PADFIELD LarrySale
27 Feb 2026, Board
- Shares
- 594
- Price
- $76.56
- Value
- $45,474
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Innospec
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 64
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- Quaker HoughtonKWR $2.68B54
- IngevityNGVT $2.14B60
- ChemoursCC $2.07B32
- Minerals TechnologiesMTX $1.93B45
- VERBIO Vereinigte BioEnergieVBK.DE $1.86B53
- CorbionCRBN.AS $1.71B66
- BorregaardBRG.OL $1.65B63
- Stepan CoSCL $1.5B51
ETFs that hold Innospec
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.